Twist Bioscience Corp: Form 10-Q for the period ended Jun 30, 2025
Filed with the SEC on Aug 4, 2025 and accepted by EDGAR at Aug 4, 2025, 16:24 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-04-01 to 2025-06-30 | $96.1m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Revenue | 9 months2024-10-01 to 2025-06-30 | $277.6m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 3 months2025-04-01 to 2025-06-30 | $44.8m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2024-10-01 to 2025-06-30 | $137.4m | us-gaap:CostOfRevenue |
| Research and development | 3 months2025-04-01 to 2025-06-30 | $18.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2024-10-01 to 2025-06-30 | $63.3m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2025-04-01 to 2025-06-30 | $63.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2024-10-01 to 2025-06-30 | $183.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2025-04-01 to 2025-06-30 | −$30.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2024-10-01 to 2025-06-30 | −$106.3m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2025-04-01 to 2025-06-30 | $191.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2024-10-01 to 2025-06-30 | $462.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2025-04-01 to 2025-06-30 | $20.4m | us-gaap:NetIncomeLoss |
| Net income | 9 months2024-10-01 to 2025-06-30 | −$50.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2025-04-01 to 2025-06-30 | $0.33 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2024-10-01 to 2025-06-30 | −$0.85 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2025-04-01 to 2025-06-30 | $0.34 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2024-10-01 to 2025-06-30 | −$0.85 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2025-04-01 to 2025-06-30 | 61,164,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2024-10-01 to 2025-06-30 | 59,600,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2024-10-01 to 2025-06-30 | −$35.8m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2024-10-01 to 2025-06-30 | $15.6m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2025-06-30 | $201.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-06-30 | $339.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2025-06-30 | $643.6m | us-gaap:Assets |
| Current liabilities | At period end2025-06-30 | $87.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-06-30 | $165.4m | us-gaap:Liabilities |
| Shareholders' equity | At period end2025-06-30 | $478.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001581280-25-000009. Last ingested by Listed: Nov 5, 2026, 16:39 ET. Listed shows no prices and gives no investment advice.